| 1.41 -0.03 (-2.08%) | 12-07 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 1.83 | 1-year : | 2.14 |
| Resists | First : | 1.57 | Second : | 1.83 |
| Pivot price | 1.3  |
|||
| Supports | First : | 0.9 | Second : | 0.5 |
| MAs | MA(5) : | 1.42 |
MA(20) : | 1.13 |
| MA(100) : | 1.19 |
MA(250) : | 1.74 |
|
| MACD | MACD : | 0.1 |
Signal : | 0.1 |
| %K %D | K(14,3) : | 84 |
D(3) : | 88.8 |
| RSI | RSI(14): 64.9 |
|||
| 52-week | High : | 3.41 | Low : | 0.5 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ HRTX ] has closed below upper band by 31.4%. Bollinger Bands are 17% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 1.47 - 1.48 | 1.48 - 1.49 |
| Low: | 1.34 - 1.35 | 1.35 - 1.36 |
| Close: | 1.4 - 1.41 | 1.41 - 1.42 |
Heron Therapeutics, Inc., a biotechnology company, engages in developing treatments to address unmet patient needs. The company's product candidates utilize its proprietary Biochronomer, a drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration. It offers SUSTOL (granisetron), an extended-release injection for the prevention of acute and delayed nausea and vomiting associated with moderately emetogenic chemotherapy, or anthracycline and cyclophosphamide combination chemotherapy regimens; and CINVANTI, an intravenous formulation of aprepitant, a substance P/neurokinin-1 receptor antagonist for the prevention of acute and delayed nausea and vomiting associated with highly emetogenic cancer chemotherapy, as well as nausea and vomiting associated with moderately emetogenic cancer chemotherapy. The company is also developing ZYNRELEF, a dual-acting local anesthetic that delivers a fixed-dose combination of the local anesthetic bupivacaine and a low dose of the nonsteroidal anti-inflammatory drug meloxicam; HTX-019, an investigational agent for the prevention of postoperative nausea and vomiting; and HTX-034 for postoperative pain management, as well as is in Phase Ib/II clinical study in patients undergoing bunionectomy. The company was formerly known as A.P. Pharma, Inc. and changed its name to Heron Therapeutics, Inc. in January 2014. Heron Therapeutics, Inc. was founded in 1983 and is headquartered in San Diego, California.
Mon, 04 Dec 2023
Should You Buy Heron Therapeutics Inc (HRTX) Stock on Monday? - InvestorsObserver
Thu, 30 Nov 2023
Why Heron Therapeutics Stock Is A Compelling Buy Into 2024 (NASDAQ:HRTX) - Seeking Alpha
Tue, 28 Nov 2023
Should You Add Heron Therapeutics Inc (HRTX) Stock to Your Portfolio Tuesday? - InvestorsObserver
Mon, 27 Nov 2023
Is Heron Therapeutics Inc (HRTX) a Good Buy in the Biotechnology Industry? - InvestorsObserver
Wed, 15 Nov 2023
Heron Therapeutics, Inc. (NASDAQ:HRTX) Q3 2023 Earnings Call Transcript - Yahoo Finance
Tue, 14 Nov 2023
Heron Therapeutics: Q3 Earnings Snapshot - Houston Chronicle
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Neutral |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 150 (M) |
| Shares Float | 114 (M) |
| Held by Insiders | 0.7 (%) |
| Held by Institutions | 92 (%) |
| Shares Short | 17,590 (K) |
| Shares Short P.Month | 19,360 (K) |
| EPS | -0.88 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | -0.21 |
| Profit Margin | -97.5 % |
| Operating Margin | -66.3 % |
| Return on Assets (ttm) | -24.6 % |
| Return on Equity (ttm) | 0 % |
| Qtrly Rev. Growth | 18.3 % |
| Gross Profit (p.s.) | -0.34 |
| Sales Per Share | 0.81 |
| EBITDA (p.s.) | -0.64 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -99 (M) |
| Levered Free Cash Flow | -51 (M) |
| PE Ratio | -1.61 |
| PEG Ratio | -0.1 |
| Price to Book value | -7.05 |
| Price to Sales | 1.72 |
| Price to Cash Flow | -2.15 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|